Differences in alpha 2u-globulins increased in male rat kidneys following treatment with several alpha 2u-globulin accumulating agents: cystein protease(s) play(s) an important role in production of kidney-type-alpha 2u-globulin.
Effects of alpha 2u-globulin accumulating agents on alpha 2u-globulins in rat kidneys were examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting analysis. Treatment of male animals with decalin (150 mg/kg), 2,2,4-trimethylpentane (50 mg/kg), isophorone (150 mg/kg), d-limonene (150 mg/kg) or 1,4-dichlorobenzene (150 mg/kg) by gavage for 14 consecutive days in each case resulted in a marked intensification of a protein band corresponding to kidney-type-alpha 2u-globulin, with a molecular mass calculated to be approximately 16 kDa. However, intraperitoneal treatment with leupeptin and E-64 (two times 0.07 mmol/kg, for each), well known cystein protease inhibitors, while only slightly increasing this kidney-type-alpha 2u-globulin band, caused the intensification of a approximately 19-kDa molecular mass protein band which was revealed to be a native-type-alpha 2u-globulin by SDS-PAGE and immunoblotting. These results indicated that at least two types of alpha 2u-globulin can be increased in male rat kidney by chemical treatment. Moreover, cystein protease(s) appear(s) to play an important role in the degradation of alpha 2u-globulin and particularly in the conversion of native-type-alpha 2u-globulin to kidney-type-alpha 2u-globulin in rat kidneys.
D000510:Alpha-Globulins / Q000096:biosynthesis*; D000818:Animals; D002722:Chlorobenzenes / Q000494:pharmacology; D003512:Cyclohexanones / Q000494:pharmacology; D053138:Cyclohexenes; D003546:Cysteine Endopeptidases / Q000502:physiology*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D015151:Immunoblotting; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D000077222:Limonene; D008297:Male; D009281:Naphthalenes / Q000494:pharmacology; D009795:Octanes / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013729:Terpenes / Q000494:pharmacology
D000510:Alpha-Globulins; D002722:Chlorobenzenes; D003512:Cyclohexanones; D053138:Cyclohexenes; D015853:Cysteine Proteinase Inhibitors; D007976:Leupeptins; D009281:Naphthalenes; D009795:Octanes; D013729:Terpenes; C013803:alpha 2u globulin; C005940:isophorone; C007229:decalin; D000077222:Limonene; C018511:4-dichlorobenzene; D003546:Cysteine Endopeptidases; D007930:Leucine; C032854:leupeptin; C045798:2,2,4-trimethylpentane; C024974:E 64